2023
Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use
Clark K, Victoria-Castro A, Ghazi L, Yamamoto Y, Coronel-Moreno C, Kadhim B, Riello R, O'Connor K, Ahmad T, Wilson F, Desai N. Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use. JACC Heart Failure 2023, 12: 322-332. PMID: 37943221, DOI: 10.1016/j.jchf.2023.08.025.Peer-Reviewed Original ResearchBest practice alertMineralocorticoid receptor antagonistsNovel potassium bindersPotassium bindersEligible patientsUsual careEjection fractionSerum potassiumHistory of hyperkalemiaIncidence of hyperkalemiaStrong guideline recommendationsHeart failure hospitalizationReduced ejection fractionLaboratory test valuesPopulation health outcomesHyperkalemia treatmentMRA prescriptionAntagonist useFailure hospitalizationPatient characteristicsSecondary outcomesHeart failurePrimary outcomeGuideline recommendationsOutpatient visits
2019
Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
Desai N, Rowan C, Alvarez P, Fogli J, Toto R. Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients. Journal Of Drug Assessment 2019, 8: 2-2. PMCID: PMC6764378, DOI: 10.1080/21556660.2019.1658287.Peer-Reviewed Original ResearchContinuous exposureRenin angiotensin aldosterone system inhibitor therapyAldosterone system inhibitor therapyDevelopment of hyperkalemiaCornerstone of therapyRetrospective cohort studyOptum Clinformatics DataMartMEq/LNational Health InsuranceBinder therapyHK cohortHyperkalemia treatmentPotassium bindersRAASi therapyIndex dateCohort studyInhibitor therapyContinuation ratesMean ageDiagnosis codesITT groupCardiovascular diseaseClinformatics DataMartMedicare patientsPatiromer